Defibrotide Therapy for SARS-CoV2 (COVID-19) Acute Respiratory Distress Syndrome (ARDS)

NCT04530604 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

13

Enrollment

OTHER

Sponsor class

Conditions

COVID
Sars-CoV2
COVID-19
Acute Respiratory Distress Syndrome

Interventions

DRUG: Defibrotide

Sponsor

Gregory Yanik

Collaborators

[object Object]